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axons bilaterally in prefrontal cortex, this surgical proce-
dure represents a human model of single traumatic brain 
injury with severe axonal damage and no external impact. 
We examined cortical tissues at the leucotomy site and at 
both prefrontal cortex rostral and frontal cortex caudal to the 
leucotomy site. For comparison, we analyzed brain tissues 
at equivalent neuroanatomical sites from non-leucotomized 
patients with schizophrenia, matched in age and gender. All 
five leucotomy cases revealed severe white matter damage 
with dense astrogliosis at the axotomy site and also neurofi-
brillary tangles and p-tau immunoreactive neurites in the 
overlying gray matter. Four cases displayed p-tau immuno-
reactivity in neurons, astrocytes and cell processes encom-
passing blood vessels at cortical sulcal depths in irregular 
patterns, similar to CTE. The three cases with apolipopro-
tein E ε4 haplotype showed scattered β-amyloid plaques 
Abstract Chronic traumatic encephalopathy (CTE) is a 
neurodegenerative disease associated with repetitive mild 
impact traumatic brain injury from contact sports. Recently, 
a consensus panel defined the pathognomonic lesion for 
CTE as accumulations of abnormally hyperphosphorylated 
tau (p-tau) in neurons (neurofibrillary tangles), astrocytes 
and cell processes distributed around small blood vessels 
at sulcal depths in irregular patterns within the cortex. The 
pathophysiological mechanism for this lesion is unknown. 
Moreover, a subset of CTE cases harbors cortical β-amyloid 
plaques. In this study, we analyzed postmortem brain tissues 
from five institutionalized patients with schizophrenia and 
history of surgical leucotomy with subsequent survival of at 
least another 40 years. Because leucotomy involves severing 
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in the overlying gray matter, but not the two cases with 
apolipoprotein E ε3/3 genotype. Brain tissue samples from 
prefrontal cortex rostral and frontal cortex caudal to the 
leucotomy site, and all cortical samples from the non-leu-
cotomized patients, showed minimal p-tau and β-amyloid 
pathology. These findings suggest that chronic axonal dam-
age contributes to the unique pathology of CTE over time.
Keywords Traumatic brain injury · Chronic traumatic 
encephalopathy · Axonal injury · Tau · Neurofibrillary 
tangle · β-Amyloid plaque
Introduction
In 2010 an estimated 2.5 million persons suffered from 
traumatic brain injury (TBI) in the United States, of whom 
50,000 died from the injury and another 2,80,000 required 
hospitalization [36]. For survivors, TBI is a known environ-
mental risk factor for the development of dementia later in 
life. Multiple studies provide evidence that single moderate 
or severe TBI increases the likelihood of eventual presenta-
tion with clinical signs and symptoms of neurodegeneration, 
such as Alzheimer Disease (AD) [7, 29, 35]. Such studies 
typically did not include postmortem examinations of brain 
tissues. Rather, the medical literature scantily addressed 
chronic neuropathological sequelae after TBI. One recent 
autopsy study of 39 patients with long-term survival 
(1–47 years) after single moderate or severe TBI, however, 
showed widespread β-amyloid plaques and neurofibrillary 
tangles (NFTs) in the brains of approximately one-third of 
patients [17]. Whether single mild TBI (concussion) simi-
larly confers increased risk of developing dementia with 
neuropathological abnormalities in susceptible individuals 
remains undetermined.
For contact sport athletes with repetitive mild TBIs or 
subconcussive events, such as boxers and American football 
players, studies of postmortem brains from symptomatic 
patients revealed a progressive neurodegenerative disorder 
with distinctive neuropathological features, called chronic 
traumatic encephalopathy (CTE) [4, 27]. Often presenting 
with symptoms years after cessation of contact sport par-
ticipation, CTE patients tend to exhibit initially behavioral 
and mood abnormalities, cognitive impairments and chronic 
headache, whereas in advanced stages, these patients dete-
riorate to frank dementia [28, 33, 45]. Like other neurode-
generative tauopathies, disease progression relates to the 
burgeoning spread of abnormally hyperphosphorylated tau 
protein (p-tau) [28]. In the first consensus meeting to define 
neuropathological criteria for CTE, the participants estab-
lished the pathognomonic lesion as p-tau accumulation in 
neurons (NFTs), astrocytes and cell processes, with predi-
lection around small blood vessels, at sulcal depths in irreg-
ular cortical spatial patterns [26]. The biological mechanism 
underlying this observation is unknown. In addition, a sub-
set of reported CTE cases demonstrated diffuse, or more 
rarely neuritic, β-amyloid plaques [4, 26, 39, 44].
TBIs commonly involve axonal injury, a prominent fac-
tor contributing to symptomatology and one of multiple 
possible lesions in the human brain consequent to head 
impact [15, 34, 46]. Therefore, we identified a human 
model that isolates the axonal damage component of TBI, 
that is, surgical leucotomy, and then tested the hypothesis 
that chronic axonal injury can result in neurodegenerative 
changes, such as NFTs and β-amyloid plaques. We analyzed 
postmortem brain tissues from five institutionalized patients 
with schizophrenia, who had undergone bilateral prefrontal 
leucotomy as therapy prior to 1953 and then lived at least 
another 40 years (Table 1). Since leucotomy involves sev-
ering axons in the prefrontal cortex, this surgical procedure 
represents a single iatrogenic TBI with severe axonal dam-
age and no external cortical impact. We examined cortical 
tissues at the leucotomy site, prefrontal cortex rostral and 
frontal cortex caudal to the leucotomy site, and hippocam-
pus for evidence of p-tau and β-amyloid accumulations. 
We also examined postmortem cortical brain tissues of five 
patients with schizophrenia from the same institution, who 
had not undergone leucotomies in their lifetimes, matched 
in gender and approximate age (±4 years) to the leucotomy 
patients (Table 1). Moreover, we determined the apolipo-
protein E (APOE) genotype for all ten patients. We found 
p-tau accumulations in the gray matter at the axotomy site 
in all five leucotomy patients, with four cases showing the 
pathognomonic p-tau pattern of CTE. Scattered β-amyloid 
plaques also occupied the gray matter at the lesion site, but 
in the three leucotomy patients with APOE ε4 haplotype. 
Table 1  Demographic features 
of five schizophrenia patients 
in leucotomy cohort and five 
schizophrenia patients without 
leucotomy in comparative 
cohort
Case number  
(leucotomy)
Age (years) Gender Case number  
(no leucotomy)
Age (years) Gender
1 67 Male 6 67 Male
2 70 Female 7 70 Female
3 77 Female 8 77 Female
4 87 Male 9 83 Male
5 89 Female 10 86 Female
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We observed minimal p-tau and β-amyloid pathology in the 
cortical samples rostral and caudal to the leucotomy site and 
in all cortical samples from the non-leucotomized schizo-
phrenia patients.
Materials and methods
All brain tissues for this study were obtained from the brain 
bank at the Pilgrim Psychiatric Center in West Brentwood, 
NY. The Pilgrim Psychiatric Center opened in 1931 as a site 
for care and treatment of patients with chronic psychiatric 
conditions. The patient population continually expanded 
such that the institution cared for almost 14, 000 patients in 
1954. Many resident patients suffered from chronic schizo-
phrenia. In the late 1940s until 1953, surgeons commonly 
performed bilateral prefrontal leucotomy as therapy for 
intractable symptoms. Currently available clinical records 
do not detail the surgical procedure, but based on autopsy 
findings and medical literature, the surgeons most likely 
used bilateral burr holes at the coronal suture between the 
frontal and parietal bones to access the brain [5]. In recent 
years, many patients have been discharged to the care of 
local community mental health centers. Several hundred 
patients, however, were too impaired for community liv-
ing and thus remained as inpatients. Drs. Kenneth Davis 
and Vahram Haroutunian established the brain bank for the 
Pilgrim Psychiatric Center, with Dr. Daniel Perl serving as 
neuropathologist.
We sampled brain specimens fixed in formalin, embed-
ded these tissues in paraffin and then sectioned the tissue 
blocks at 5 μm thickness. For the leucotomy postmortem 
brain tissues, the samples comprised cortical tissues cut 
in the coronal plane at the leucotomy site, prefrontal cor-
tex rostral and frontal cortex caudal to the leucotomy site, 
and hippocampus; for the non-leucotomized postmortem 
brain tissues, the samples included equivalent cortical neu-
roanatomical sites. We conducted hematoxylin and eosin 
(H&E) stains on tissue sections for general morphology/
structure and immunohistochemistry with antibodies detect-
ing glial fibrillary acidic protein (GFAP, astrocyte marker, 
mouse anti-human monoclonal antibody GA5, Leica Bio-
systems, PA0026), abnormally hyperphosphorylated tau 
(AT8, pS199/S202/T205; mouse anti-human monoclonal 
antibody, Thermo Scientific, MN1020), β-amyloid (mouse 
anti-human monoclonal antibody, clone 6F/3D, Leica Bio-
systems, NCL-B-Amyloid) and antigen CD68 (marker of 
macrophages and activated microglia, mouse anti-human 
monoclonal antibody clone 514H12, Leica Biosystems, 
PA0273). Immunohistochemistry for these antibodies was 
performed on a Leica Bond III automated immunostainer 
with a diaminobenzidine (DAB) chromogen detection sys-
tem (Leica Biosystems, DS9800, Buffalo Grove, IL).
We also performed immunohistochemistry experiments 
with two other antibodies against abnormally hyperphos-
phorylated tau (CP13, pS202; PHF1, pS396/S404). Briefly, 
tissue sections were first deparaffinized and rehydrated. For 
antigen retrieval, tissue sections were immersed in sodium 
citrate buffer (pH 6) at boiling temperature for 6 min and 
then cooled to room temperature. To quench endogenous 
peroxidase activity, tissue sections were placed in a solu-
tion of 0.5% H2O2 in methanol for 1 h. Tissue sections 
were incubated in blocking solution, comprised of 5% 
bovine serum albumin in phosphate-buffered saline (pH 
7.4), for 1 h at room temperature. The primary antibodies 
were diluted in block solution (CP13, mouse anti-human 
monoclonal antibody, 1:1000; PHF1, mouse anti-human 
monoclonal antibody, 1:1000; gifts from Dr. Peter Davies, 
Feinstein Institute for Medical Research, Manhasset, NY). 
The tissue sections were incubated with primary antibody 
solution in a humidified chamber at 4 °C overnight. Tis-
sue sections were then incubated with secondary antibody, 
followed by avidin–biotin-complex incubation (Vectastain 
Elite ABC Kit, mouse IgG, Vector Laboratories, PK-6102) 
and visualization with DAB (ImmPACT DAB, Vector Labo-
ratories, SK-4105, Burlingame, CA), according to manu-
facturer instructions. The sections were counterstained with 
hematoxylin, dehydrated and cleared with xylene before 
application of mounting media and coverslip.
Tissue samples also underwent modified Bielschowsky 
silver staining for detection of NFTs and neuritic plaques 
[8]. We extracted DNA from formalin-fixed brain tissues, 
according to manufacturer’s instructions (DNeasy Blood & 
Tissue Kit, QIAGEN, 69504, Valencia, CA). APOE geno-
typing was performed with real-time polymerase chain reac-
tion (RT-PCR) [2].
Two neuropathologists (DI, DPP) conducted blinded 
evaluations of the stained and immunostained brain tissue 
samples. This protocol received Institutional Review Board 
approval prior to initiation of study.
Results
Schizophrenia patients with leucotomy
The leucotomized schizophrenia cohort comprised five 
patients with advanced years at the time of death (mean 
age 78 years, range 67–89 years, 3 females and 2 males, 
Table 1). In the standard leucotomy operation, surgeons 
sectioned axons in white matter of both frontal lobes 
in the plane of the coronal suture (Fig. 1a) [5]. In all five 
cases, the leucotomy site in the prefrontal cortex displayed 
severe white matter damage on both gross examination and 
H&E staining (Fig. 1b, c). GFAP immunoreactivity indi-
cated replacement of subcortical white matter with dense 
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astrogliosis (Fig. 4a, c, e). The prefrontal cortical sample 
rostral to the leucotomy site showed intact white matter in 
case 1. For case 2, GFAP immunohistochemistry showed 
scattered, sparse astrogliosis. For case 3, GFAP immuno-
reactivity revealed minimal astrogliosis, and cases 4 and 5 
showed moderate astrogliosis. In the frontal cortical sam-
ples caudal to the leucotomy site, GFAP immunoreactiv-
ity displayed nominal white matter astrogliosis (Table 2). 
CD68 immunoreactivity was unremarkable in all samples.
Because the consensus panel for CTE diagnosis rec-
ommended AT8 or equivalent p-tau antibodies (CP13 and 
PHF1), we conducted immunohistochemistry experiments 
with these three antibodies [26]. All five leucotomy cases 
showed heightened p-tau immunoreactivity in the cortex 
at the coronal plane of the axotomy site, specifically NFTs 
and p-tau immunoreactive neurites (Fig. 2b, e, h). The 
white matter of cases 1, 4 and 5 revealed rare, isolated p-tau 
immunoreactive threads. Unlike the cortex at the leucotomy 
site, the prefrontal rostral cortical tissues of cases 1, 2 and 
5 showed no immunoreactivity with AT8, CP13 or PHF1 
antibodies, and cases 3 and 4 displayed scant NFTs and 
p-tau immunoreactive neurites (Fig. 2a, d, g). Frontal corti-
cal tissues caudal to the leucotomy site similarly revealed 
minimal p-tau pathology. For cases 1, 2, 4 and 5, no p-tau 
immunoreactivity was detected with AT8, CP13 or PHF1 
immunohistochemistry at these sites (Fig. 2c, f, i). AT8 and 
CP13 immunohistochemistry revealed scant NFTs and p-tau 
immunoreactive neurites in case 3 (Table 2). For all cases, 
the AT8 and CP13 antibodies showed correspondent immu-
noreactivity, whereas PHF1 immunoreactivity revealed less 
p-tau pathology in these tissue samples (Fig. 3j–l).
In the prefrontal cortex at the leucotomy site, immunohis-
tochemistry with antibodies AT8 and CP13 revealed at least 
one sulcal depth with primarily astrocytic tangles and p-tau 
immunoreactive cell processes, including not only perivascu-
lar ensheathment, in gray matter of cases 2–5, but also few 
scattered NFTs either within the cortical layers of the sulcal 
depth or the two apposing gyri forming the sulcus (Fig. 3a–
l). Cortical sulcal depths with p-tau immunoreactivity ori-
ented in irregular patterns, often with one immunopositive 
sulcal depth next to sulcal depths without p-tau immunore-
activity within the same tissue slide. In addition, prefrontal 
rostral cortex for case 3 displayed a focus of subpial p-tau in 
one sulcal depth with the CP13 and AT8 antibodies, but not 
the PHF1 antibody (Table 2). In cortical sulcal depths with 
p-tau immunoreactivity, GFAP immunoreactivity in serial 
tissue sections was likewise increased (Fig. 4a–f).
For cases 1, 3 and 4, β-amyloid immunoreactivity and 
modified Bielschowsky silver stains exhibited diffuse and 
cored plaques in gray matter at the leucotomy site, but no 
neuritic plaques or cerebral amyloid angiopathy (CAA) 
(Fig. 5b, e, h). Case 2 showed no evidence of β-amyloid 
pathology with either immunohistochemistry or Biels-
chowsky staining methods. Case 5, the oldest patient in 
the cohort at 87 years, displayed a small focus of cored 
and diffuse plaques with additional subpial immunoreac-
tivity at one sulcal depth, which did not correspond to the 
p-tau immunoreactivity pattern and also differed from 
the β-amyloid plaques distributed throughout gray matter 
at the leucotomy site in cases 1, 3 and 4. APOE genotyp-
ing revealed ε4 haplotype for cases 1, 3 and 4 (ε3/4, ε2/4 
and ε3/4, respectively), but genotypes ε3/3 for cases 2 and 
5 (Table 3). Similar to the p-tau pathology patterns, corti-
cal tissues rostral and caudal to the leucotomy site showed 
minimal β-amyloid pathology. The prefrontal rostral corti-
cal samples from all five cases were negative for β-amyloid 
plaques (Fig. 5a, d, g). Case 1 showed minimal leptomenin-
geal CAA. For the frontal caudal cortical samples, cases 2 








Fig. 1  Neuroanatomical sampling sites and macroscopic findings in 
postmortem brains of leucotomized schizophrenia patients. The red 
bar indicates the approximate location of cortex overlying the leuco-
tomy site; the white bars show the three neuroanatomical sites for the 
cortical/subcortical samples (prefrontal cortex rostral to leucotomy, 
prefrontal cortex at leucotomy site and frontal cortex caudal to leu-
cotomy) (a). Coronal gross appearance at the level of the leucotomy 
site revealing severe white matter damage, with tissue loss and cyst 
formation, and relative sparing of gray matter (b). H&E stain shows 
white matter rarefaction and tissue loss, with intact cerebral cortex 
(c). Case 5 (b, c)
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cases 4 and 5 exhibited few cored plaques in gray matter 
(Fig. 5c, f, i). Case 1 displayed one blood vessel with CAA 
in gray matter (Table 2). No β-amyloid immunoreactivity 
was detected in white matter.
We also examined tissues sections from the hippocam-
pus. In CTE, NFTs and other p-tau pathologies preferen-
tially affect the CA2 and CA4 regions of the hippocampus, 
which differs from CA1 and subiculum involvement in nor-
mal aging or AD [26]. Cases 1 and 2 (ages 67 and 70 years, 
respectively) showed rare, isolated NFTs in CA1 and no 
β-amyloid plaques (Fig. 6a, b). Cases 3, 4 and 5 (ages 77, 
87 and 89 years, respectively) revealed moderate NFTs in 
CA1, several individual NFTs in subiculum and entorhinal 
cortex, and diffuse and cored plaques in the entorhinal cor-
tex (Fig. 6c–h). These p-tau and β-amyloid pathologies are 
consistent with aging, as opposed to CTE pathology.
Schizophrenia patients without leucotomy
For comparison, we selected a cohort of five non-leu-
cotomized schizophrenia patients who had lived in the 
same institution, matched in gender and approximate age 
(±4 years) at the time of death (mean age 77 years, range 
67–86 years, 3 females and 2 males, Table 1). We studied 
brain specimens from identical cortical sites as the leuco-
tomy patients. All tissue samples showed no significant 
pathology. GFAP and CD68 immunoreactivities were unre-
markable. The cortical tissues revealed rare, scattered NFTs 
and β-amyloid plaques, but no p-tau encompassing blood 
vessels or favoring sulcal depths. Case 10 showed nominal 
CAA (Table 2). These five schizophrenia patients genotyped 
either as APOE ε3/3 or ε3/4 (Table 3).
Discussion
In this study, we isolated the axonal injury component 
of human TBI by examining brain tissues from deceased 
patients with schizophrenia, who had undergone leuco-
tomies at least 40 years before death. We specifically ana-
lyzed these tissues for chronic neurodegenerative sequelae. 
We provided evidence that massive chronic axonal damage 
in white matter of prefrontal cortex, as produced by leuco-




Fig. 2  P-tau pathology in cortex adjacent to leucotomy site. NFTs 
and p-tau immunoreactive neurites in cortex at leucotomy site (b, e, 
h), but minimal p-tau pathology in cortex rostral (a, d, g) or caudal 
(c, f, i) to the leucotomy site. Case 1 (a, b, c). Case 2 (d–f). Case 4 (g, 
h, i). AT8 immunohistochemistry (a–i). Scale bars a–i 100 μm
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and cell processes, particularly around small blood vessels 
at depths of cortical sulci in irregular spatial patterns, in 
gray matter adjacent, but not rostral or caudal, to the axot-
omy site. This specific cortical p-tau distribution matches 
the recently established pathognomonic lesion of CTE, sug-
gesting that axonal injury may serve as a pathophysiologi-
cal substrate for this pathology over time, and possibly for 
both repetitive mild TBIs of contact sports and single severe 
or even moderate impact head injuries. Last, the brains of 
schizophrenia patients with leucotomy formed β-amyloid 
plaques in gray matter also adjacent to the axotomy site, 
but predominantly in those patients with the APOE ε4 hap-
lotype. We did not observe comparable p-tau or β-amyloid 
accumulations in corresponding neuroanatomical prefrontal 
cortices as the axotomy sites in the non-leucotomized schiz-
ophrenia patients of matched age and gender, nor in corre-
sponding rostral prefrontal or caudal frontal cortical sites.
CTE is a distinct neurodegenerative disorder linked to 
previous repetitive mild impact TBI and subconcussive 
events, classically described in retired boxers [4, 24]. The 
recent publication establishing initial diagnostic criteria 
for CTE points to p-tau accumulations in neurons, astro-
cytes and cell processes, favoring ensheathment of blood 
vessels at sulcal depths in irregular cortical patterns, as the 
pathognomonic lesion, thus distinguishing CTE from other 
neurodegenerative tauopathies and also aging-related tau 
Fig. 3  P-tau pathology at sulcal depths in cortex adjacent to leuco-
tomy site. Primarily astrocytic tangles and p-tau immunoreactive 
cell processes at cortical sulcal depths, including distribution around 
small blood vessels (a–l). NFTs at cortical sulcal depth (h). AT8, 
CP13 and PHF1 immunoreactivities at cortical sulcal depth in serial 
tissue sections (j–l). Case 3 (a–d). Case 4 (e, f). Case 5 (g–l). AT8 (a–
c, e–h, j), CP13 (d, i, k) and PHF1 (l) immunohistochemistry. Scale 
bars a, d, e 200 μm, c, f–h, j–l 100 μm, b, i 50 μm
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astrogliopathy (ARTAG) [19, 26]. The underlying patho-
physiology leading to this specific neuroanatomical distri-
bution of p-tau aggregates, especially encompassing blood 
vessels, remains unanswered. There are two main hypoth-
eses: that underlying axonal damage may be related to these 
pathognomonic lesions or that mechanical stress at sulcal 
depths during the traumatic event may render them suscep-
tible to eventual p-tau deposition. Due to lack of extensive 
clinical history, we cannot comment upon head injury for 
an individual patient in this study. Nevertheless, because we 
observed p-tau immunoreactivity patterns similar to CTE 
only in the schizophrenia patients with leucotomy, which 
results in severe axonal injury without head impact, the 
data in this study support the hypothesis that selective p-tau 
accumulation at sulcal depths relates to underlying axonal 
damage.
Evidence exists to support the connection between trau-
matic axonal damage, which can persist for years, and 
accumulation of protein aggregates typically associated 
with neurodegenerative disease, with particular research 
focus on β-amyloid [14, 16, 43]. Pointedly, among those 
patients who had died or experienced temporal cortex sur-
gical resection shortly after severe TBI, a subset showed 
β-amyloid plaques, including young people [10, 40, 41]. In 
diffuse axonal injury resultant of impact TBI, disruption of 
protein transport at sites of damage can lead to accumula-
tion of proteins, including amyloid precursor protein (APP), 
in axonal varicosities and bulbs [16]. With axonal dam-
age, proteins can abnormally congregate in the same space, 
either within the damaged axon or extracellular domain. As 
such, noxious molecular interactions potentially can occur, 
for example, β-secretase and presenilin-1 cleaving APP to 
generate β-amyloid that can then aggregate to form plaques 
[3, 16, 43, 49]. Likewise, indigenous tau proteins normally 
reside within axons, stabilizing neuronal microtubules to 
aid with axonal transport of essential components necessary 
for cell survival and function. With tauopathic neurodegen-
erative disease, tau proteins become hyperphosphorylated, 
disassociate from microtubules and aggregate in insoluble 
form. One postmortem study of human brain tissues, from 
Fig. 4  P-tau and GFAP pathol-
ogy in cortex and subcortical 
white matter at leucotomy site. 
GFAP immunoreactivity in 
white matter showing severe 
astrogliosis (a, c, e). GFAP and 
p-tau immunoreactivities at 
corresponding sulcal depths in 
serial tissue sections (a–f). Case 
5 (a, b). Case 3 (c, d). Case 4 
(e, f). GFAP (a, c, e) and p-tau 
(b, d, f) immunohistochemistry. 
Scale bars a, b 200 μm, c–f 
500 μm
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persons who had died between 4 h and 5 weeks after TBI, 
showed PHF1 immunopositivity in axonal varicosities and 
bulbs, neuronal cell bodies and reactive astrocytes within 
the cerebral cortex in two of 18 cases [49]. In the TBI 
study of surgically resected temporal cortices, tissue sam-
ples in 12 of 18 cases displayed dystrophic axons in white 
matter with positive PHF1 immunoreactivity; three cases 
showed PHF1 immunopositive glia, and four cases revealed 
PHF1 immunopositive neurons [10]. For the schizophrenia 
patients who had survived at least 40 years after leucotomy 
in this study, we similarly noted NFTs, astrocytic tangles 
and p-tau immunoreactive cell processes in neuroanatomi-
cal areas near the axotomy site, with three p-tau antibod-
ies including PHF1. In addition, we observed β-amyloid 
plaques scattered in the gray matter within proximity of 
the massive axonal damage in a subset of the leucotomized 
Fig. 5  β-Amyloid pathology in cortex adjacent to leucotomy site. 
In leucotomized schizophrenia patients with APOE ε4 haplotype, 
β-amyloid plaques in cortex at leucotomy site (b, e, h), but minimal 
β-amyloid pathology in cortex rostral (a, d, g) or caudal (c, f, i) to 
the leucotomy site. Case 1 (a, b, c). Case 3 (d, e, f). Case 4 (g, h, i). 
β-amyloid immunohistochemistry (a–i). Scale bars a–i–100 μm
Table 3  Apolipoprotein genotype of leucotomized and comparative non-leucotomized schizophrenia patients
For cases 1–5, positive (+) and negative (−) findings at the leucotomy site for both abnormally hyperphosphorylated tau in cortical neurons, 
astrocytes or cell processes, and β-amyloid plaques distributed throughout gray matter
APOE apolipoprotein E, p-tau abnormally hyperphosphorylated tau
Case number  
(leucotomy)
APOE genotype Leucotomy site Case number (no leucotomy) APOE genotype
β-Amyloid plaques p-Tau
1 ε3/4 + + 6 ε3/3
2 ε3/3 − + 7 ε3/4
3 ε2/4 + + 8 ε3/4
4 ε3/4 + + 9 ε3/3
5 ε3/3 − + 10 ε3/4
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cases (APOE ε4 haplotype). Given these data and literature, 
we surmise that damaged axons may inadvertently release 
proteins at the lesion site into the extracellular brain paren-
chyma, perhaps over long periods of time, thereby promot-
ing aberrant molecular reactions and deleterious aggrega-
tion of particular proteins.
One possible explanation for the p-tau accumulation pat-
tern in CTE, and the leucotomized patients in this study, lies 
in interstitial solute clearance in the human brain through local 
diffusion and fluid bulk flow, a process first proposed about 
100 years ago with recent scientific breakthroughs [12]. The 
human brain lacks characteristic lymphatic vessels, utilized 
by the rest of the body, to provide protein and fluid homeo-
stasis. In contemporary experiments involving rodents, data 
show that cerebrospinal fluid (CSF) in the subarachnoid space 
influxes through periarterial spaces and exits through the aqua-
porin 4 channels of astrocytic endfeet, mixes with interstitial 
fluid to flow by convection through the interstitial space clear-
ing macromolecules and finally passes through aquaporin 4 
channels of astrocytic endfeet into perivenous spaces—termed 
Fig. 6  P-tau and β-amyloid 
pathology in hippocampus of 
leucotomized schizophrenia 
patients. Rare, isolated NFTs in 
CA1 of the two younger cases 
and moderate NFTs in CA1 
of the three older cases (a, c, 
e), but no β-amyloid immu-
noreactivity (b, d, f). Several 
individual NFTs and β-amyloid 
plaques in the entorhinal cortex 
in the three older cases (g, 
h). Case 2 (a, b). Case 3 (c, 
d). Case 5 (e, f). AT8 (a, c, e, 
g) and β-amyloid (b, d, f, h) 
immunohistochemistry. Scale 
bars a–f, h; 100 μm, e; 200 μm
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the glymphatic pathway for the dependence upon glial cells to 
function as the surrogate lymphatic system in the brain [30]. 
The perivenous fluid effluxes to contiguous CSF that filtrates 
through arachnoid granulations to dural sinuses for venous 
drainage. Two recent papers provide evidence that CSF, with 
its soluble and cellular contents, flows into newly discovered 
lymphatic vessels in meninges lining dural sinuses that drain 
into cervical lymph nodes [1, 23], in addition to lymphatic 
vessels of nasal mucosa, cranial nerve sheathes and par-
ticular arteries and veins exiting the cranium [1]. In another 
paper employing mouse models, the authors showed impaired 
function of the glymphatic system after TBI, with prominent 
astrogliosis, loss of perivascular aquaporin 4 polarization and 
axonal damage and then specifically identified diminished 
interstitial tau clearance with accompanying hyperphosphoryl-
ated tau increase [11]. One common observation reported in 
CTE, and also in the leucotomy patients of this study, is p-tau 
accumulation encompassing blood vessels and in perivascular 
astrocytes, which is consistent with clearance data in rodents. 
Considered a biomarker for axonal injury, total tau levels 
increase in CSF and blood serum after TBI in humans, includ-
ing contact sports athletes shortly after mild head injuries [31, 
42, 50]. Nevertheless, since most experiments involve rodents, 
with lissencephalic brain structures, the specific mechanisms 
of clearance within the human brain, particularly its relation to 
sulcal depths, remain poorly understood. We suspect that the 
sulcal depth serves as an exodus for tau clearance after axonal 
damage in humans. If true, then axonal injury, which occurs 
with TBI ranging from mild to severe, may account for the 
pathognomonic p-tau signature pattern of CTE [26]. Finally, 
brain tissues from long-term survivors of single moderate to 
severe TBI, with presumable axonal injuries that can persist 
for years, also display NFTs and p-tau immunoreactive astro-
cytes in cortical sulcal depths [14, 17]. Taken together, these 
data and literature not only bolster the link between head 
trauma and CTE, but also attenuate the notion of the pathog-
nomonic CTE lesion being limited to multiple mild TBIs and/
or subconcussive events.
CTE is classified as a tauopathy, yet a subset of reported 
cases displays diffuse or neuritic β-amyloid plaques in corti-
cal gray matter, which instigated the debate decades ago con-
cerning the pathophysiologic connections among head injury, 
neuropathological neurodegenerative indicators such as p-tau 
and β-amyloid protein accumulations and augmented develop-
ment of neurodegenerative diseases. In 1973, after extensive 
examination of brain tissues from 15 deceased boxers, Cor-
sellis, et al. reported only one case with neuritic β-amyloid 
plaques, using classic silver staining techniques [4]. Interest-
ingly, Roberts, et al. analyzed brain tissues from 14 of these 
same cases plus six others, but additionally employed immu-
nohistochemistry experiments for β-amyloid detection, to dis-
cover numerous diffuse plaques in most cases [39]. Moreover, 
several papers provide data suggesting an association between 
the APOE ε4 genotype and predilection for β-amyloid deposi-
tion in the brains of patients dying shortly after head injury [9, 
32] and also in CTE patients especially with advancing years 
[44]. In this present study, all three leucotomized patients with 
the APOE ε4 haplotype displayed diffuse and cored β-amyloid 
plaques scattered throughout the gray matter adjacent to the 
lesion site, in contrast to the leucotomized patients with the 
APOE ε3/3 genotype. The oldest leucotomized patient, who 
had died at 87 years with an APOE ε3/3 genotype, showed a 
focus of cored β-amyloid plaques at one sulcal depth, which 
complements a recent study reporting predilection of β-amyloid 
aggregates at cortical sulcal depths in CTE patients [44]. All 
five schizophrenia patients without leucotomies showed mini-
mal or no β-amyloid immunoreactivity in cortical gray matter, 
including three patients with APOE ε4 haplotype. The molecu-
lar interaction between ApoE protein and β-amyloid warrants 
further clarification; however, ApoE can bind β-amyloid to 
enhance its clearance through multiple mechanisms including 
proteolysis, with ApoE E4 as the least effective isoform [22]. 
In mouse models, experimental data demonstrated that murine 
brains clear soluble β-amyloid along glymphatic paravenous 
drainage pathways as well and that deletion of the Aqp4 gene 
attenuates this process [13]. In addition to the glymphatic sys-
tem for clearance of β-amyloid, efflux transporters, such as 
the low-density lipoprotein receptor-related protein-1 (LRP1), 
facilitate transendothelial transport across the blood–brain bar-
rier [51, 52]. Human brain studies revealed cerebrovascular 
β-amyloid deposits in three former boxers and increased fre-
quency of CAA in APOE ε4 patients with severe acute TBI 
[21, 48]. In this study, we observed minimal CAA or perivas-
cular β-amyloid aggregation in all ten schizophrenia patients. 
Rather, brain tissues of the APOE ε4 haplotype patients with 
leucotomy showed β-amyloid plaques throughout gray matter 
overlying the axotomy site.
This study has several limitations in design and inter-
pretation. Foremost, we lacked detailed antemortem clini-
cal data, including head injury history, which curtailed 
the extent of neuropathological analysis. Additionally, we 
assessed brain tissues from two small cohorts: five schizo-
phrenia patients with leucotomy and for comparison, five 
schizophrenia patients without leucotomy who had also 
lived at the Pilgrim Psychiatric Center during approximately 
the same time period. Most likely aging in the schizophrenic 
brain diverges from persons without this condition, as evi-
denced by schizophrenia patients in advanced years more 
frequently suffering from severe cognitive impairments 
than the general population [37, 38]. A neuropathologi-
cal study of 100 consecutive autopsy patients (age range, 
52–101 years; mean, 77 years), however, shows equiva-
lent amounts of β-amyloid plaques and NFTs in neocortex 
and hippocampus of patients with schizophrenia, as com-
pared to 47 patients with other psychiatric disorders and 
50 patients without psychiatric or dementing diagnoses, 
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when matched by age [37]. The study authors concluded 
that the percentage of elderly schizophrenia patients with 
AD, as determined by neuropathological criteria, basically 
equates to the general elderly population with correspond-
ing ages. Since schizophrenia involves neurodevelopmental 
abnormalities, the possibility exists that clearance of p-tau, 
β-amyloid and other neurodegenerative proteins may differ 
from persons without schizophrenia. Due to the small num-
ber of patients in each cohort, uncertainty of tissue integrity 
equivalence from archived brain specimens and tendency 
for focality and irregularity patterns of especially the p-tau 
immunoreactivity, we did not numerically quantify patho-
logical results. Also, because we obtained specimens previ-
ously dissected for other studies, we were unable to analyze 
hemibrain sections similar to contemporary CTE studies to 
attain more thorough neuroanatomical distribution assess-
ment of p-tau aggregates in sulcal depths. As such, we could 
not determine potential cortical spatial patterns for sul-
cal tauopathy, which currently are described as irregular in 
CTE. Furthermore, given these limiting circumstances, we 
may have serendipitously missed sulcal tauopathy in the 
sampling of brain tissues from case 1. Other possibilities 
for lack of sulcal p-tau pathology in case 1 include that this 
individual responded differently than the other four patients 
after the leucotomy procedure, or that since this patient died 
at the youngest age (67 years), with more prolonged life this 
patient may have accumulated p-tau in sulcal depths similar 
to the other older leucotomized patients in the cohort.
In summary, we studied a human model of severe axonal 
injury, analyzing brain tissues specifically for chronic neu-
rodegenerative changes. We found p-tau pathology in pat-
terns resembling CTE in gray matter adjacent to the leucot-
omy site. We also observed a subset of cases with β-amyloid 
plaques, similarly reported in CTE, scattered in gray matter 
at the leucotomy site, but in patients with APOE ε4 haplo-
type, which is associated with worse clinical outcomes for 
TBI patients [6, 25, 47], including boxers and American 
football players [18, 20]. These data suggest that axonal 
injury, common to all severities of TBI, contributes to the 
distinct pathology of CTE over time.
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